4D Molecular Therapeutics Inc
NASDAQ:FDMT
4D Molecular Therapeutics Inc
NASDAQ:FDMT
Price:
9.84
USD
-2.57%
Market Closed
Market Cap:
$501.9m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
4D Molecular Therapeutics Inc
NASDAQ:FDMT
|
US |
|
Shenzhen Forms Syntron Information Co Ltd
SZSE:300468
|
CN |
|
C
|
Chagee Holdings Ltd
NASDAQ:CHA
|
CN |
|
R
|
Ruchi Infrastructure Ltd
NSE:RUCHINFRA
|
IN |
|
Ameren Corp
NYSE:AEE
|
US |
|
Sensei Biotherapeutics Inc
F:407
|
US |
|
Goodtech ASA
OSE:GOD
|
NO |
|
Merko Ehitus AS
F:MKS
|
EE |
|
NRG Energy Inc
NYSE:NRG
|
US |
|
Akeso Inc
OTC:AKESF
|
CN |
Balance Sheet
Balance Sheet Decomposition
4D Molecular Therapeutics Inc
4D Molecular Therapeutics Inc
Balance Sheet Decomposition is not available for
4D Molecular Therapeutics Inc
4D Molecular Therapeutics Inc
Balance Sheet
4D Molecular Therapeutics Inc
4D Molecular Therapeutics Inc
Currency: USD
| Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | Dec-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Cash & Cash Equivalents |
24
|
92
|
50
|
277
|
153
|
52
|
249
|
149
|
60
|
|
| Cash Equivalents |
24
|
92
|
50
|
277
|
153
|
52
|
249
|
149
|
60
|
|
| Short-Term Investments |
0
|
0
|
0
|
0
|
95
|
161
|
39
|
276
|
342
|
|
| Total Receivables |
0
|
1
|
1
|
2
|
0
|
0
|
0
|
0
|
0
|
|
| Accounts Receivables |
0
|
1
|
1
|
2
|
0
|
0
|
0
|
0
|
0
|
|
| Other Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Assets |
0
|
1
|
2
|
4
|
9
|
7
|
8
|
10
|
10
|
|
| Total Current Assets |
25
|
94
|
53
|
283
|
256
|
221
|
297
|
435
|
413
|
|
| PP&E Net |
3
|
3
|
5
|
5
|
29
|
35
|
32
|
41
|
33
|
|
| PP&E Gross |
3
|
3
|
5
|
5
|
29
|
35
|
32
|
41
|
33
|
|
| Accumulated Depreciation |
1
|
2
|
3
|
4
|
5
|
8
|
12
|
17
|
21
|
|
| Long-Term Investments |
0
|
0
|
0
|
0
|
68
|
5
|
11
|
81
|
111
|
|
| Other Long-Term Assets |
0
|
0
|
1
|
1
|
1
|
1
|
1
|
4
|
9
|
|
| Total Assets |
27
N/A
|
97
+255%
|
58
-40%
|
288
+395%
|
354
+23%
|
262
-26%
|
340
+30%
|
560
+65%
|
567
+1%
|
|
| Liabilities | ||||||||||
| Accounts Payable |
1
|
1
|
2
|
2
|
5
|
3
|
4
|
4
|
11
|
|
| Accrued Liabilities |
1
|
2
|
3
|
5
|
7
|
10
|
14
|
22
|
30
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Liabilities |
5
|
6
|
8
|
10
|
4
|
2
|
2
|
3
|
3
|
|
| Total Current Liabilities |
6
|
8
|
13
|
17
|
16
|
16
|
19
|
29
|
44
|
|
| Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Liabilities |
23
|
14
|
15
|
15
|
18
|
15
|
13
|
21
|
17
|
|
| Total Liabilities |
28
N/A
|
22
-24%
|
28
+31%
|
32
+13%
|
34
+8%
|
31
-11%
|
32
+5%
|
50
+55%
|
61
+23%
|
|
| Equity | ||||||||||
| Common Stock |
19
|
103
|
103
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Retained Earnings |
21
|
30
|
79
|
136
|
207
|
315
|
415
|
576
|
716
|
|
| Additional Paid In Capital |
1
|
2
|
6
|
392
|
527
|
547
|
723
|
1 087
|
1 221
|
|
| Other Equity |
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
1
|
|
| Total Equity |
1
N/A
|
75
N/A
|
30
-60%
|
256
+755%
|
319
+24%
|
231
-28%
|
308
+33%
|
511
+66%
|
506
-1%
|
|
| Total Liabilities & Equity |
27
N/A
|
97
+255%
|
58
-40%
|
288
+395%
|
354
+23%
|
262
-26%
|
340
+30%
|
560
+65%
|
567
+1%
|
|
| Shares Outstanding | ||||||||||
| Common Shares Outstanding |
5
|
5
|
5
|
27
|
32
|
33
|
43
|
46
|
58
|
|
Switch to:
Switch to:
See Also
Discover More
